Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial

Gastroenterology

Volumn 117, Issue 6, 1999, Pages 1271-1277

  Ehrenpreis, E D ^a   Kane, S V ^a   Cohen, L B ^a   Cohen, R D ^a   Hanauer, S B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; IMMUNOSUPPRESSIVE AGENT; MAGNESIUM HYDROXIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE; STEROID; THALIDOMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONSTIPATION; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RASH; SEDATION; STEROID THERAPY;

EID: 0032714591     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(99)70276-3     Document Type: Article

References (33)

1. SR Targan SB Hanauer SJ van Deventer L Mayer DH Present T Braakman KL DeWoody TF Schaible PJ Rutgeerts A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease Crohn's Disease cA2 Study Group N Engl J Med 337 1997 1029 1035
2. DH Present P Rutgeerts S Targan SB Hanauer L Mayer RA van Hogezand DK Podolsky BE Sands T Braakman KL DeWoody TF Schaible SJ van Deventer Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398 1405
3. S Murch CP Braegger JA Walker-Smith TT MacDonald Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease Gut 34 1993 1705 1709
4. PK Peterson S Hu WS Sheng FH Kravitz TW Molitor D Chatterjee CC Chao Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells J Infect Dis 172 1995 1137 1140
5. SM McHugh IR Rifkin J Deighton AB Wilson PJ Lachmann CM Lockwood PW Ewan The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures Clin Exp Immunol 99 1995 160 167
6. G Reyes-Teran JG Sierra-Madero V Martinez del Cerro H Arroyo-Figueroa A Pasquetti JJ Calva GM Ruiz-Palacios Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial Aids 10 1996 1501 1507
7. RJ Stevens C Andujar CJ Edwards Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients Br J Rheumatol 36 1997 353 359
8. GB Vogelsang ER Farmer AD Hess V Altamonte WE Beschorner DA Jabs RL Corio LS Levin OM Colvin JR Wingard GW Santos Thalidomide for the treatment of chronic graft-versus-host disease N Engl J Med 326 1992 1055 1058
9. A Hauschild H Kroeger NA Mitchison S Ugrinovic K Zwingenberger Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift Clin Exp Immunol 108 1997 428 431
10. MS Hecker MG Lebwohl Recalcitrant pyoderma gangrenosum: treatment with thalidomide J Am Acad Dermatol 38 1998 490 491
11. P Calderon M Anzilotti R Phelps Thalidomide in dermatology. New indications for an old drug Int J Dermatol 36 1997 881 887
12. EB Odeka V Miller Thalidomide in oral Crohn's disease refractory to conventional medical treatment (letter; comment) J Pediatr Gastroenterol Nutr 25 1997 250 251
13. AR Wettstein AP Meaghan Thalidomide in Crohn's disease Lancet 350 1997 1445 1446
14. RC Hastings JR Traut CD Enna RR Jacobson Thalidomide in the treatment of erythema nodosum leprosum Clin Pharmacol Ther 11 1970 481 487
15. JM Jacobson JS Greenspan J Spritzler N Ketter JL Fahey JB Jackson L Fox M Chernoff AW Wu LA MacPhail GJ Vasquez DA Wohl Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection N Engl J Med 336 1997 1487 1493
16. DH Present BI Korelitz N Wisch JL Glass DB Sachar BS Pasternack Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study N Engl J Med 302 1980 981 987
17. N Myatt G Coghill K Morrison D Jones IA Cree Detection of tumour necrosis factor in sarcoidosis and tuberculosis granulomas using in situ hybridization J Clin Pathol 47 1994 423 426
18. SM McHugh TL Rowland Thalidomide and derivatives: immunological investigations of tumour necrosis factor–alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation Clin Exp Immunol 110 1997 151 154
19. SC Ball KA Sepkowitz JL Jacobs Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: case report and review Am J Gastroenterol 92 1997 169 170
20. LN Alexander CM Wilcox A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers AIDS Res Hum Retroviruses 13 1997 301 304
21. DA Lewis CN Amerasinghe SM Murphy Successful treatment of Behçet's syndrome in an African female patient with thalidomide Int J STD AIDS 7 1996 518 520
22. L Rousseau M Beylot-Barr y MS Doutre C Beylot Cutaneous sarcoidosis successfully treated with low doses of thalidomide (letter) Arch Dermatol 134 1998 1045 1046
23. C Macumber AP Wettstein CR Vickers M Hing PD Edwards DJ Byrnes AP Meagher Thalidomide-effective therapy in chronic resistant inflammatory bowel disease (abstr) Gastroenterology 116 suppl 1999 A767
24. SV Kane ED Ehrenpreis LB Cohen Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (abstr) Gastroenterology 116 suppl 1999 A475
25. EA Vasiliauskas LY Kam MT Abreu-Martin KA Papadakis JB Zeldis SR Targan An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance and efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-dependent Crohn's disease (abstr) Gastroenterology 116 suppl 1999 A837
26. S Wedel J Bauditz A Suk H Lochs Efficacy of thalidomide in Crohn's disease (abstr) Gastroenterology 116 suppl 1999 A843
27. SJ van Deventer Tumor necrosis factor and Crohn's disease Gut 40 1997 443 448
28. TT MacDonald P Hutchings MY Choy S Murch A Cooke Tumour necrosis factor–alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine Clin Exp Immunol 81 1990 301 305
29. HM Van Dullemen SJH van Deventer DW Hommes HA Bijl J Jansen GNJ Tytgat J Woody Treatment of Crohn's disease with anti–tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109 1995 129 135
30. RP McCabe J Woody SJH van Deventer SR Targan L Mayer R van Hogezand P Rutgerts SB Hanaver DK Podolsky CO Elson A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease (abstr) Gastroenterology 110 suppl 1996 3759
31. WA Stack SD Mann AJ Roy P Heath M Sopwith J Freeman G Holmes R Long A Forbes MA Kamm Randomized controlled trial of CDP571 antibody to tumour necrosis factor–alpha in Crohn's disease Lancet 349 1997 521 524
32. EJ Ir vine Usual therapy improves perianal Crohn's disease as measured by a new disease activity index J Clin Gastroenterol 20 1995 27 32
33. CC Harland GB Steventon JR Marsden Thalidomide-induced neuropathy and genetic differences in drug metabolism Eur J Clin Pharmacol 49 1995 1 6